Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024

白血病治療薬の世界市場予測(~2024年)

◆タイトル:Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024
◆商品コード:PH 1254
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年5月27日
◆ページ数:90
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

この研究は、白血病治療薬市場の現在の規模を推定する上で4つの活動を軸に進めました。まず、市場とそのサブセグメントに関する情報を収集する目的で、二次調査を余すところなく行いました。次のステップでは、一次調査を通じてバリューチェーン全体の業界専門家と共にこれらの調査結果、前提条件、および規模を検証しました。市場規模全体を見積もるために、トップダウンとボトムアップの両方のアプローチを採用しました。その後、市場の内訳とデータの三角測量を使用して、セグメントとサブセグメントの市場規模を推定しました。当調査レポートでは、白血病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類(CLL、ALL、CML、AML)別分析、治療の種類(化学療法、分子標的治療)別分析、投薬経路(経口、注射)別分析、分子タイプ(小分子、生物製剤)別分析、白血病治療薬の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The study involved four major activities in estimating the current size of the leukemia therapeutics market. Exhaustive secondary research was done to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as leukemia drug manufacturers, vendors, distributors and scientists, researchers, oncologist, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by the significant use of immunotherapies and targeted drugs for leukemia treatment owing to the increasing incidence rate of leukemia across the globe. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:

Note 1: C-level primaries include chief executive officers (CEOs), chief operation officers (COOs), and chief financial officers (CFOs). D-level primaries include directors, managers, and heads of departments. Others include sales managers, marketing managers, and product managers.
Note 2: Company tiers are defined by their total revenues. As of 2017, Tier 1: >USD 1 billion; Tier 2: USD 50 million to USD 1 billion; and Tier 3: <50 million.
“To know about the assumptions considered for the study, download the pdf brochure.”
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the leukemia therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
 The key players in the industry and markets have been identified through extensive secondary research
 The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
 All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the leukemia industry.
Report Objectives

• To define, describe, and forecast the leukemia therapeutics market on the basis of type, application, and region
• To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities)
• To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukemia therapeutics market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
• To forecast the size of the market segments in four geographical regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
• To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
• To track and analyze competitive developments such as product launches, partnerships, expansions, and acquisitions in the leukemia therapeutics market
Scope of the Report
Report Metric Details
Market Size Available for Years 2017–2024
Base Year Considered 2018
Forecast Period 2019–2024
Forecast Units Value (USD)
Segments Covered Leukemia therapeutics market by treatment type, type of leukemia, gender, molecule type, mode of administration, and region
Geographies Covered North America (US, Canada), Europe (Germany, France, UK, and the RoE), APAC (Japan, China, Australia, and the RoAPAC), and the RoW
Companies Covered Major 10 players covered—Novartis (Switzerland), AbbVie (US), Bristol-Myers Squibb (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US)

This research report categorizes the leukemia therapeutics market into the following segments and subsegments:
LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA
• Acute lymphocytic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
• Acute myeloid leukemia (AML)
• Chronic myeloid leukemia (CML)
LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE
• Targeted drugs & immunotherapy
• Chemotherapy
LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE
• Small Molecules
• Biologics

LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION
• Injectable
• Oral
LEUKEMIA THERAPEUTICS MARKET, BY GENDER
• Male
• Female
LEUKEMIA THERAPEUTICS MARKET, BY REGION
 North America
 US
 Canada
 Europe
 Germany
 UK
 France
 Rest of Europe
 Asia Pacific
 China
 Japan
 India
 Rest of Asia Pacific
 Rest of the World


Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
• Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
• Geographic Analysis: Further breakdown of the European, Asia Pacific, and the Rest of the World segments into their respective countries for this market
• Company Information: Detailed analysis and profiling of additional market players (up to 5)
• Volume Data: Customization options for volume data (number of units sold) and customization options for volume data (number of tests)
• Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Related Reports:
• INTERVENTIONAL ONCOLOGY MARKET – GLOBAL FORECAST TO 2024
By Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis)
https://www.marketsandmarkets.com/Market-Reports/interventional-oncology-market-203687164.html

• STEM CELL ASSAY MARKET – GLOBAL FORECAST TO 2023
By Type (Viability, Purification, Identification), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instruments, Kits), Application (Regenerative Medicine, Clinical Research), End User
https://www.marketsandmarkets.com/Market-Reports/stem-cell-assay-market-47610330.html

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.2.1 MARKETS COVERED 15
1.2.2 YEARS CONSIDERED FOR THE STUDY 15
1.3 CURRENCY 16
1.4 LIMITATIONS 16
1.5 STAKEHOLDERS 16
2 RESEARCH METHODOLOGY 17
2.1 RESEARCH DATA 17
2.2 SECONDARY DATA 17
2.2.1 KEY DATA FROM SECONDARY SOURCES 18
2.3 PRIMARY DATA 18
2.3.1 KEY DATA FROM PRIMARY SOURCES 20
2.4 MARKET SIZE ESTIMATION 21
2.4.1 BOTTOM-UP APPROACH 21
2.4.2 TOP-DOWN APPROACH 22
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.6 ASSUMPTIONS FOR THE STUDY 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHTS 29
4.1 LEUKEMIA THERAPEUTICS: MARKET OVERVIEW 29
4.2 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE & MODE OF
ADMINISTRATION (2019) 30
4.3 GEOGRAPHICAL SNAPSHOT OF THE LEUKEMIA THERAPEUTICS MARKET 31
5 MARKET OVERVIEW 32
5.1 INTRODUCTION 32
5.2 MARKET DYNAMICS 32
5.2.1 DRIVERS 33
5.2.1.1 Rising prevalence of leukemia 33
5.2.1.1.1 Growth in geriatric population 33
5.2.1.1.2 Rising cancer occurrence among children 33
5.2.1.2 Introduction of innovative therapies 34
5.2.2 RESTRAINTS 34
5.2.2.1 Complexities in manufacturing 34
5.2.3 OPPORTUNITIES 35
5.2.3.1 Growth opportunities in emerging economies 35
6 LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA 36
6.1 INTRODUCTION 37
6.2 CHRONIC MYELOID LEUKEMIA 37
6.2.1 CHRONIC MYELOID LEUKEMIA ACCOUNTS FOR THE LARGEST SHARE OF
THE LEUKEMIA THERAPEUTICS MARKET PRIMARILY DUE TO THE HIGH INCIDENCE OF THIS DISEASE WORLDWIDE 37
6.3 CHRONIC LYMPHOCYTIC LEUKEMIA 38
6.3.1 THE INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA INCREASES WITH
AGE AND IS MORE COMMON IN MEN THAN WOMEN 38
6.4 ACUTE LYMPHOCYTIC LEUKEMIA 39
6.4.1 ACUTE LYMPHOCYTIC LEUKEMIA MOSTLY AFFECTS CHILDREN BETWEEN
3 AND 7 YEARS OF AGE 39
6.5 ACUTE MYELOID LEUKEMIA 40
6.5.1 ACUTE MYELOID LEUKEMIA IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS 40
7 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 41
7.1 INTRODUCTION 42
7.2 TARGETED DRUGS & IMMUNOTHERAPY 42
7.2.1 TARGETED DRUGS & IMMUNOTHERAPY SEGMENT ACCOUNTS FOR THE LARGER MARKET SHARE DUE TO THE HIGHER EFFICACY & SUCCESS RATE ASSOCIATED WITH THEM AS COMPARED TO CHEMOTHERAPY 42
7.3 CHEMOTHERAPY 46
7.3.1 CHEMOTHERAPY IS EFFECTIVE AND ESSENTIAL FOR CANCERS SUCH AS LEUKEMIA THAT HAVE SPREAD THROUGHOUT THE BODY 46
8 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE 50
8.1 INTRODUCTION 51
8.2 SMALL MOLECULES 51
8.2.1 THE SMALL STRUCTURE AND CHEMICAL COMPOSITION OF SMALL MOLECULES HELP THEM TO EASILY PENETRATE CELL MEMBRANES 51
8.3 BIOLOGICS 53
8.3.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 53
9 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION 54
9.1 INTRODUCTION 55
9.2 ORAL MODE 55
9.2.1 DRUGS ADMINISTERED ORALLY HAVE LESSER COMPLICATIONS 55
9.3 INJECTABLE MODE 56
9.3.1 INJECTABLE MODE OF ADMINISTRATION IS LESS PREFERRED THAN
THE ORAL MODE OF ADMINISTRATION 56
10 LEUKEMIA THERAPEUTICS MARKET, BY GENDER 58
10.1 INTRODUCTION 59
10.2 MALES 60
10.2.1 MEN ARE AT HIGHER RISK OF DEVELOPING LEUKEMIA THAN WOMEN 60
10.3 FEMALES 61
10.3.1 ACUTE LYMPHOCYTIC LEUKEMIA REMAINS COMMON AMONG WOMEN 61
11 LEUKEMIA THERAPEUTICS MARKET, BY REGION 62
11.1 INTRODUCTION 63
11.2 NORTH AMERICA 64
11.2.1 US 66
11.2.1.1 US accounted for the largest share of the North American market due to the high prevalence of leukemia in the country 66
11.2.2 CANADA 70
11.2.2.1 Government initiatives to support leukemia research and develop novel immunotherapies is expected to support the growth of the Canadian leukemia therapeutics market 70
11.3 EUROPE 71
11.3.1 GERMANY 73
11.3.1.1 Germany has a strong foundation for R&D, including over 1,000 public and private institutions 73
11.3.2 UK 74
11.3.2.1 Rising geriatric population in the country to drive market growth as the incidence of cancer is higher in the geriatric population 74
11.3.3 FRANCE 79
11.3.3.1 Rising R&D expenditure is a major growth driver in France 79
11.3.4 REST OF EUROPE 80
11.4 ASIA PACIFIC 82
11.4.1 JAPAN 83
11.4.1.1 Comparatively lenient regulations and rising geriatric population will drive market growth 83
11.4.2 CHINA 85
11.4.2.1 Favorable investments and government support will contribute to
the growth of the Chinese market 85
11.4.3 INDIA 86
11.4.3.1 Shortage of skilled professionals may restrain the growth of
the Indian market 86
11.4.4 ROAPAC 88
11.5 REST OF THE WORLD 90

12 COMPETITIVE LANDSCAPE 92
12.1 OVERVIEW 92
12.2 MARKET RANKING ANALYSIS, 2018 92
12.3 KEY STRATEGIES 93
12.3.1 REGULATORY APPROVALS/LAUNCHES 93
12.3.2 ACQUISITIONS 94
12.3.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 95
12.4 COMPETITIVE LEADERSHIP MAPPING (2018) 96
12.4.1 VENDOR INCLUSION CRITERIA 96
12.4.2 VISIONARY LEADERS 96
12.4.3 INNOVATORS 96
12.4.4 DYNAMIC DIFFERENTIATORS 96
12.4.5 EMERGING COMPANIES 96
12.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018) 98
12.5.1 PROGRESSIVE COMPANIES 98
12.5.2 STARTING BLOCKS 98
12.5.3 RESPONSIVE COMPANIES 98
12.5.4 DYNAMIC COMPANIES 98
13 COMPANY PROFILES 100
(Business Overview, Products Offered, Recent Developments, Regulatory Approvals, and MnM View)*
13.1 NOVARTIS AG 100
13.2 ABBVIE 102
13.3 BRISTOL-MYERS SQUIBB 105
13.4 F. HOFFMANN-LA ROCHE 107
13.5 SANOFI 109
13.6 PFIZER 110
13.7 AMGEN 112
13.8 GILEAD SCIENCES 114
13.9 TAKEDA 116
13.10 CELGENE 118
* Business Overview, Products Offered, Recent Developments, Regulatory Approvals, and MnM View might not be captured in case of unlisted companies.
14 APPENDIX 120
14.1 INSIGHTS FROM INDUSTRY EXPERTS 120
14.2 DISCUSSION GUIDE 121
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 124
14.4 AVAILABLE CUSTOMIZATIONS 126
14.5 RELATED REPORTS 126
14.6 AUTHOR DETAILS 127

LIST OF TABLES

TABLE 1 LEUKEMIA PATIENTS, BY REGION 33
TABLE 2 ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS IN US 34
TABLE 3 LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 37
TABLE 4 CHRONIC MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION) 38
TABLE 5 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, BY REGION,
2017–2024 (USD MILLION) 39
TABLE 6 ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY REGION,
2017–2024 (USD MILLION ) 39
TABLE 7 ACUTE MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION) 40
TABLE 8 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 42
TABLE 9 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 43
TABLE 10 TARGETED DRUGS AND IMMUNOTHERAPY MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 43
TABLE 11 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 44
TABLE 12 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 44
TABLE 13 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 45
TABLE 14 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 45
TABLE 15 FEW EXAMPLES OF CHEMOTHERAPY DRUGS 46
TABLE 16 CHEMOTHERAPY MARKET FOR LEUKEMIA, BY REGION,
2017–2024 (USD MILLION) 46
TABLE 17 CHEMOTHERAPY MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION) 47
TABLE 18 CHEMOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 47
TABLE 19 CHEMOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 48
TABLE 20 CHEMOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION,
2017–2024 (USD MILLION) 48
TABLE 21 CHEMOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION,
2017–2024 (USD MILLION) 49
TABLE 22 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE,
2017–2024 (USD MILLION) 51
TABLE 23 FEW IMPORTANT SMALL MOLECULES USED TO TREAT DIFFERENT LEUKEMIA TYPE 52
TABLE 24 LEUKEMIA THERAPEUTICS MARKET FOR SMALL MOLECULES, BY REGION,
2017–2024 (USD MILLION) 52
TABLE 25 FEW IMPORTANT BIOLOGICS FOR THE TREATMENT OF DIFFERENT LEUKEMIA TYPE 53
TABLE 26 LEUKEMIA THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION,
2017–2024 (USD MILLION) 53
TABLE 27 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION,
2017–2024 (USD MILLION) 55
TABLE 28 LEUKEMIA THERAPEUTICS MARKET FOR ORAL MODE OF ADMINISTRATION,
BY REGION, 2017–2024 (USD MILLION) 56
TABLE 29 LEUKEMIA THERAPEUTICS MARKET FOR INJECTABLE MODE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION) 57
TABLE 30 LEUKEMIA AT A GLANCE (US) 59
TABLE 31 GLOBAL LEUKEMIA CASES (2018), BY COUNTRY AND GENDER &
FORECAST (2020) 59
TABLE 32 LEUKEMIA INCIDENCE AND DEATHS, BY GENDER (2018) 60
TABLE 33 LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 60
TABLE 34 LEUKEMIA THERAPEUTICS MARKET FOR MALES, BY REGION,
2017–2024 (USD MILLION) 61
TABLE 35 LEUKEMIA THERAPEUTICS MARKET FOR FEMALES, BY REGION,
2017–2024 (USD MILLION) 61
TABLE 36 LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 37 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 65
TABLE 38 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 65
TABLE 39 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION) 65
TABLE 40 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 66
TABLE 41 US: LEUKEMIA AT A GLANCE 66
TABLE 42 US: LEUKEMIA, BY TYPE (2017 VS. 2018) 67
TABLE 43 US: LEUKEMIA NEW CASES & DEATHS, BY STATE (2019) 67
TABLE 44 US: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 69
TABLE 45 US: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 69
TABLE 46 US: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 70
TABLE 47 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 70
TABLE 48 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 71
TABLE 49 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 71
TABLE 50 RESEARCH FUNDING: EUROPEAN OVERVIEW 71
TABLE 51 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 72
TABLE 52 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 72
TABLE 53 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 72
TABLE 54 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 73
TABLE 55 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 73
TABLE 56 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 74
TABLE 57 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 74
TABLE 58 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATE PER 100,000 POPULATION (ACUTE LYMPHOCYTIC LEUKEMIA) 75
TABLE 59 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC LYMPHOCYTIC LEUKEMIA) 76
TABLE 60 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (ACUTE MYELOID LEUKEMIA) 76
TABLE 61 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC MYELOID LEUKEMIA) 77
TABLE 62 UK: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 78
TABLE 63 UK: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 78
TABLE 64 UK: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 78
TABLE 65 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 79
TABLE 66 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 79
TABLE 67 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 80
TABLE 68 ROE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 81
TABLE 69 ROE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 81
TABLE 70 ROE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 81
TABLE 71 APAC: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 82
TABLE 72 APAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 82
TABLE 73 APAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 83
TABLE 74 APAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 83
TABLE 75 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 84
TABLE 76 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 84
TABLE 77 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 85
TABLE 78 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 85
TABLE 79 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 86
TABLE 80 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 86
TABLE 81 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 87
TABLE 82 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 87
TABLE 83 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 87
TABLE 84 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 88
TABLE 85 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 88
TABLE 86 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 89
TABLE 87 ROW: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION) 90
TABLE 88 ROW: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION) 90
TABLE 89 ROW: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION) 91
TABLE 90 LEUKEMIA THERAPEUTICS MARKET RANKING BY KEY PLAYER, 2018 92


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 17
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 19
FIGURE 3 LEUKEMIA THERAPEUTICS MARKET: BOTTOM-UP APPROACH 21
FIGURE 4 LEUKEMIA THERAPEUTICS MARKET: TOP-DOWN APPROACH 22
FIGURE 5 DATA TRIANGULATION METHODOLOGY 23
FIGURE 6 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2019 VS. 2024 (USD MILLION) 25
FIGURE 7 LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2019 VS. 2024 (USD MILLION) 26
FIGURE 8 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION,
2019 VS. 2024 (USD MILLION) 26
FIGURE 9 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE,
2019 VS. 2024 (USD MILLION) 27
FIGURE 10 LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2019 VS. 2024 (USD MILLION) 27
FIGURE 11 LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2019 VS. 2024 (USD MILLION) 28
FIGURE 12 RISING INCIDENCE RATE OF LEUKEMIA TO DRIVE MARKET GROWTH 29
FIGURE 13 ORAL AND TARGETED DRUGS & IMMUNOTHERAPY SEGMENTS TO DOMINATE
THE MARKET IN 2019 30
FIGURE 14 US TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 31
FIGURE 15 LEUKEMIA THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 32
FIGURE 16 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET SNAPSHOT 64
FIGURE 17 KEY DEVELOPMENTS IN THE LEUKEMIA THERAPEUTICS MARKET (2016-2018) 92
FIGURE 18 MNM DIVE-VENDOR COMPARISON MATRIX: LEUKEMIA THERAPEUTICS MARKET 97
FIGURE 19 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS:
LEUKEMIA THERAPEUTICS MARKET 99
FIGURE 20 NOVARTIS: COMPANY SNAPSHOT (2018) 100
FIGURE 21 ABBVIE INC.: COMPANY SNAPSHOT (2018) 102
FIGURE 22 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2018) 105
FIGURE 23 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2018) 107
FIGURE 24 SANOFI: COMPANY SNAPSHOT (2018) 109
FIGURE 25 PFIZER: COMPANY SNAPSHOT (2018) 110
FIGURE 26 AMGEN: COMPANY SNAPSHOT (2018) 112
FIGURE 27 GILEAD SCIENCES: COMPANY SNAPSHOT (2018) 114
FIGURE 28 TAKEDA: COMPANY SNAPSHOT (2018) 116
FIGURE 29 CELGENE: COMPANY SNAPSHOT (2018) 118


★調査レポート[白血病治療薬の世界市場予測(~2024年)] ( Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024 / PH 1254) 販売に関する免責事項
[白血病治療薬の世界市場予測(~2024年)] ( Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024 / PH 1254) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆